These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 31153668

  • 1. [Effect of physical exercise on Alzheimer's disease. A sistematic review].
    Agüera Sánchez MÁ, Barbancho Ma MÁ, García-Casares N.
    Aten Primaria; 2020 May; 52(5):307-318. PubMed ID: 31153668
    [Abstract] [Full Text] [Related]

  • 2. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia.
    Román G, Pascual B.
    Arch Med Res; 2012 Nov; 43(8):671-6. PubMed ID: 23142262
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y, Ito K, Arima K, Matsuda H, Nakata Y, Sakata M, Sato N, Nakagome K, Motohashi N.
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [Abstract] [Full Text] [Related]

  • 4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, Houot M, Lista S, Cacciamani F, Potier MC, Bertrand A, Lamari F, Benali H, Mangin JF, Colliot O, Genthon R, Habert MO, Hampel H, INSIGHT-preAD study group.
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [Abstract] [Full Text] [Related]

  • 5. Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type.
    Whitwell JL, Kantarci K, Weigand SD, Lundt ES, Gunter JL, Duffy JR, Strand EA, Machulda MM, Spychalla AJ, Drubach DA, Petersen RC, Lowe VJ, Jack CR, Josephs KA.
    J Alzheimers Dis; 2015 Apr; 45(4):1109-17. PubMed ID: 25649655
    [Abstract] [Full Text] [Related]

  • 6. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
    Yokoyama S, Kajiya Y, Yoshinaga T, Tani A, Hirano H.
    Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
    [Abstract] [Full Text] [Related]

  • 7. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, Christensen JJ, Morris JC, Yablonskiy DA.
    Neuroimage; 2017 Mar 01; 148():296-304. PubMed ID: 27989773
    [Abstract] [Full Text] [Related]

  • 8. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Banerjee G, Kim HJ, Fox Z, Jäger HR, Wilson D, Charidimou A, Na HK, Na DL, Seo SW, Werring DJ.
    Brain; 2017 Apr 01; 140(4):1107-1116. PubMed ID: 28335021
    [Abstract] [Full Text] [Related]

  • 9. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2015 Apr 01; 7():105-13. PubMed ID: 25610772
    [Abstract] [Full Text] [Related]

  • 10. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.
    Int J Geriatr Psychiatry; 2015 May 01; 30(5):505-13. PubMed ID: 25043833
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2018 May 01; 19():190-201. PubMed ID: 30023169
    [Abstract] [Full Text] [Related]

  • 12. Molecular neuroimaging in degenerative dementias.
    Jiménez Bonilla JF, Carril Carril JM.
    Rev Esp Med Nucl Imagen Mol; 2013 May 01; 32(5):301-9. PubMed ID: 23933381
    [Abstract] [Full Text] [Related]

  • 13. Molecular neuroimaging in Alzheimer's disease.
    Matsuda H, Imabayashi E.
    Neuroimaging Clin N Am; 2012 Feb 01; 22(1):57-65, viii. PubMed ID: 22284733
    [Abstract] [Full Text] [Related]

  • 14. Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area.
    Walters MJ, Sterling J, Quinn C, Ganzer C, Osorio RS, Andrews RD, Matthews DC, Vallabhajosula S, de Leon MJ, Isaacson RS, Mosconi L.
    BMJ Open; 2018 Nov 25; 8(11):e023664. PubMed ID: 30478117
    [Abstract] [Full Text] [Related]

  • 15. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
    Benvenutto A, Giusiano B, Koric L, Gueriot C, Didic M, Felician O, Guye M, Guedj E, Ceccaldi M.
    J Alzheimers Dis; 2018 Nov 25; 65(4):1147-1157. PubMed ID: 30124446
    [Abstract] [Full Text] [Related]

  • 16. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BN, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD.
    Brain; 2016 Sep 25; 139(Pt 9):2528-39. PubMed ID: 27357349
    [Abstract] [Full Text] [Related]

  • 17. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A, Alzheimer's Disease Neuroimaging Initiative.
    Neurobiol Aging; 2014 Jan 25; 35(1):143-51. PubMed ID: 23954175
    [Abstract] [Full Text] [Related]

  • 18. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M, Noda Y, Shinagawa S, Chung JK, Sawada K, Ogyu K, Tarumi R, Tsugawa S, Miyazaki T, Yamagata B, Graff-Guerrero A, Mimura M, Nakajima S, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2018 Jan 25; 63(2):861-869. PubMed ID: 29689728
    [Abstract] [Full Text] [Related]

  • 19. The role of PET/CT amyloid Imaging compared with Tc99m-HMPAO SPECT imaging for diagnosing Alzheimer's disease.
    Suppiah S, Ching SM, Nordin AJ, Vinjamuri S.
    Med J Malaysia; 2018 Jun 25; 73(3):141-146. PubMed ID: 29962497
    [Abstract] [Full Text] [Related]

  • 20. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B, Nation DA, Alzheimer’s Disease Neuroimaging Initiative.
    Brain; 2017 Jul 01; 140(7):1987-2001. PubMed ID: 28575149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.